ArriVent BioPharma, Inc.
$15.58-3.2%YTD-20.5%1Y-23.0%
Price updated 13m ago·X counts updated 3d ago
On X
The complete picture of $AVBP on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
188X posts · last 7 days
Chatter Meter
0.9×
How loud $AVBP's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $AVBP.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
Top industry ETF
$IBBiShares Biotechnology ETF
+17.9%YTD
+32.5%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-4.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-47.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-21.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-50.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-1.05$-0.99-6.3%
Q1 2026May 11, 2026$-0.96$-0.88-9.1%
Q4 2025Mar 5, 2026$-0.78$-0.87+10.3%
Q3 2025Nov 10, 2025$-0.83$-0.78-6.4%
Next earningsMon, Nov 16·consensus EPS $-1.06
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-1.05$-39.6M
Q1 FY26$0———$-0.96$-41.9M
Q4 FY25$0———$-0.84$-30.7M
Q3 FY25$0———$-0.83$-35.8M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$125K$64K – $213K-$4.23-$4.31 – -$4.087
FY27$7.3M$2.7M – $14.1M-$3.89-$4.63 – -$3.307
FY28$54.4M$28.0M – $92.8M-$2.73-$4.27 – $0.818
FY29$158.3M$81.4M – $270.0M-$1.32-$2.53 – -$0.496
FY30$301.6M$155.1M – $514.5M$0.83$0.30 – $1.596
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.19%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-42.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-40.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 29.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today6.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.355-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
SC 13D/AActivist amendmentOct 8SC 13D/A
8-KPress release / Reg FDOct 68-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KMaterial agreementAug 128-K — Item 1.01: Material agreement · Item 2.02: Earnings release
8-KShareholder voteJun 228-K — Item 5.07: Shareholder vote
+ 9 other (2 10-Qs · 2 13Gs · 2 proxys · 1 routine 8-K) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & KorsinskyArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS LawAVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS LawAVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 1 · last 7 days